Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline

Journal of Nuclear Medicine

Volumn 45, Issue 10, 2004, Pages 1694-1697

  Schwarz, Johannes ^a   Storch, Alexander ^b   Koch, Walter ^c   Pogarell, Oliver ^d   Radau, Perry E ^e   Tatsch, Klaus ^c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Dopamine transporter; Parkinson's disease; Rate of decline; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 123; N (3 IODOPROPENE 3 YL) 2BETA CARBOMETHOXY 3BETA (4 CHLOROPHENYL) TROPANE I 123; TROPANE DERIVATIVE; UNCLASSIFIED DRUG; CARRIER PROTEIN; DIAGNOSTIC AGENT; MEMBRANE PROTEIN; N (3 IODOPROP 2 ENYL) 2 BETA CARBOMETHOXY 3 (4 METHYLPHENYL)NORTROPANE; N-(3-IODOPROP-2-ENYL)-2-BETA-CARBOMETHOXY-3-(4-METHYLPHENYL)NORTROPANE; NERVE PROTEIN; NORTROPANE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BIOLOGICAL MODEL; BRAIN; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; HOSPITALIZATION; KINETICS; LONGITUDINAL STUDY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NONLINEAR SYSTEM; SCINTISCANNING; STATISTICAL MODEL; TISSUE DISTRIBUTION;

BRAIN; COMPUTER SIMULATION; DISEASE PROGRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FOLLOW-UP STUDIES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KINETICS; LINEAR MODELS; LONGITUDINAL STUDIES; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; NONLINEAR DYNAMICS; NORTROPANES; PARKINSON DISEASE; PROTEIN BINDING; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 14744286501     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Seibyl JP. Imaging studies in movement disorders. Semin Nucl Med. 2003;33:105-113.
2. Borbely K. Functional neuroimaging in movement disorders [in Hungarian]. Orv Hetil. 2001;142:2347-2355.
3. 123I] beta-CIT SPECT. J Neural Transm. 2000;107:543-552.
4. 123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 2001;57:2089-2094.
5. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003;74:294-298.
6. 18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314-319.
7. 18F]fluoro-L-dopa PET study. Mov Disord. 2001;16:608-615.
8. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93-101.
9. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653-1661.
10. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun. 2001;22:721-725.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
12. 123I]IPT and single-photon emission tomography. Eur J Nucl Med. 1997;24:415-421.
13. Sperfeld AD, Collatz MB, Baier H, et al. FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol. 1999;46:708-715.
14. 123I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med. 2000;27:1809-1812.
15. Slomka PJ, Radau P, Hurwitz GA, Dey D. Automated three-dimensional quantification of myocardial perfusion and brain SPECT. Comput Med Imaging Graph. 2001;25:153-164.
16. 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med. 2000;41:220-227.
17. Brooks DJ. PET and SPECT studies in Parkinson's disease. Baillieres Clin Neurol. 1997;6:69-87.
18. Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brucke T. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord. 2003;18:1266-1272.
19. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2003;60:381-389.
20. Albin RL, Frey KA. Initial agonist treatment of Parkinson disease: a critique. Neurology. 2003;60:390-394.
21. Brooks DJ. Imaging endpoints for monitoring neuroprotection in Parkinson's disease. Ann Neurol. 2003;53(suppl 3):S110-S118